Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
Abstract Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. Methods A total number of 1...
Main Authors: | Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-021-01741-9 |
Similar Items
-
Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01) -
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01) -
Primary resistance to osimertinib despite acquired T790M
by: Ling‐Kai Chang, et al.
Published: (2020-03-01) -
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01) -
EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)